China Pharma Holdings Inc (CPHI) - Total Liabilities
Based on the latest financial reports, China Pharma Holdings Inc (CPHI) has total liabilities worth $7.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CPHI financial resilience to evaluate the company's liquid asset resilience ratio.
China Pharma Holdings Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how China Pharma Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CPHI total assets.
China Pharma Holdings Inc Competitors by Total Liabilities
The table below lists competitors of China Pharma Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mortgage Advice
LSE:MAB1
|
UK | GBX93.95 Million |
|
GoldOn Resources Ltd
V:GLD
|
Canada | CA$20.70K |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
USA | $25.77 Million |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
USA | $33.70 Million |
|
Serabi Gold PLC
LSE:SRB
|
UK | GBX29.61 Million |
|
PolyPlank publ AB
ST:POLY
|
Sweden | Skr21.55 Million |
|
Ostrom Climate Solutions Inc
V:COO
|
Canada | CA$13.69 Million |
|
Apimeds Pharmaceuticals US, Inc.
NYSE MKT:APUS
|
USA | $14.70 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down China Pharma Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of China Pharma Holdings Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Pharma Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Pharma Holdings Inc (2001–2024)
The table below shows the annual total liabilities of China Pharma Holdings Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.14 Million | -20.80% |
| 2023-12-31 | $9.01 Million | -33.20% |
| 2022-12-31 | $13.49 Million | -18.87% |
| 2021-12-31 | $16.63 Million | +26.83% |
| 2020-12-31 | $13.11 Million | +0.89% |
| 2019-12-31 | $13.00 Million | -14.37% |
| 2018-12-31 | $15.18 Million | -10.09% |
| 2017-12-31 | $16.88 Million | -13.92% |
| 2016-12-31 | $19.61 Million | -20.22% |
| 2015-12-31 | $24.58 Million | -4.83% |
| 2014-12-31 | $25.83 Million | +4.71% |
| 2013-12-31 | $24.67 Million | +67.53% |
| 2012-12-31 | $14.72 Million | +5.86% |
| 2011-12-31 | $13.91 Million | +0.68% |
| 2010-12-31 | $13.81 Million | +31.00% |
| 2009-12-31 | $10.54 Million | +88.18% |
| 2008-12-31 | $5.60 Million | +42.05% |
| 2007-12-31 | $3.94 Million | -48.53% |
| 2006-12-31 | $7.66 Million | +11103.95% |
| 2005-12-31 | $68.41K | 0.00% |
| 2004-12-31 | $68.41K | -93.38% |
| 2003-12-31 | $1.03 Million | +4.09% |
| 2002-12-31 | $992.02K | 0.00% |
| 2001-12-31 | $992.02K | -- |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more